Apixaban Versus Aspirin and Risk of Hemorrhage in the ARCADIA Trial
Annals of Neurology · 2026-06 · 99 (6) · 1589-1597
DOI: 10.1002/ana.78186 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Annals of Neurology, online erschienen am 25.02.2026. Verfasst von Hooman Kamel und 15 weiteren Autor:innen. Beteiligte Einrichtung: Clinical and Translational Neuroscience Unit, Department of Neurology and Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New …. Hauptthemen laut MEDLINE: Pyridones, Pyrazoles, Aspirin, Hemorrhage. Die Arbeit nennt 31 Literaturangaben.
Abstract (Originalsprache)
Objective
The relative risks of bleeding with apixaban and aspirin remain unclear. We compared bleeding end points on apixaban versus aspirin in the ARCADIA trial.
Methods
ARCADIA was a multicenter, double‐blind, randomized trial of apixaban versus aspirin in patients with cryptogenic stroke and evidence of atrial cardiopathy. International Society on Thrombosis and Hemostasis (ISTH) criteria were used to classify bleeding as intracranial, symptomatic intracranial, major non‐intracranial hemorrhages, and any major and minor hemorrhages. We calculated annualized incidence rate differences (IRDs) between apixaban and aspirin. Our primary analysis included the safety sample which censored patients who permanently stopped taking the study drug. Sensitivity analyses included the intention‐to‐treat sample.
Results
Among 1,015 patients assigned to apixaban or aspirin and followed for a mean 1.8 (±1.2) years, 115 (11.3%) patients experienced 146 hemorrhages: 27 (18.5%) major and 119 (81.5%) minor hemorrhages. Apixaban resulted in significantly fewer intracranial hemorrhages than aspirin in both the safety sample (IRD = −1.4%, 95% confidence interval [CI] = −2.3% to −0.5%) and intention‐to‐treat sample (IRD = −1.0%, 95% CI = −1.8% to −0.2%). Findings were similar for the risk of symptomatic intracranial hemorrhage in the safety sample (IRD = −1.1%, 95% CI = −1.8% to −0.3%), although this was not statistically significant in the sensitivity analysis of the intention‐to‐treat sample (IRD = −0.7%, 95% CI = −1.4% to 0.0%, p = 0.11). Risks of major non‐intracranial hemorrhage, any major hemorrhage, and minor hemorrhage did not differ significantly between apixaban and aspirin.
Interpretation
We found no increase in any hemorrhage type and a decrease in intracranial hemorrhage with apixaban relative to aspirin in patients with cryptogenic stroke and evidence of atrial cardiopathy. ANN NEUROL 2026;99:1589–1597
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Clinical and Translational Neuroscience Unit, Department of Neurology and Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY.
- Department of Neurology, University of Washington, Seattle, WA.
- Department of Medicine, University of Washington, Seattle, WA.
- Department of Epidemiology, University of Washington, Seattle, WA.
- Department of Biostatistics, University of Washington, Seattle, WA.
- Department of Neurology, Vagelos College of Physicians and Surgeons, New York, NY.
ORCID-Profile: Hooman Kamel, Ashkan Shoamanesh, Kevin N Sheth, Babak B Navi
Zitieren
APA
Kamel, H., Longstreth, W. T., Tirschwell, D. L., Kronmal, R. A., Elkind, M. S. V., Pauls, Q., Garcia, R. A., Plummer, P., Sabagha, N., Ammar, A., Healey, J. S., Shoamanesh, A., Sheth, K. N., Broderick, J. P., Navi, B. B., & ARCADIA Investigators (2026). Apixaban Versus Aspirin and Risk of Hemorrhage in the ARCADIA Trial. Annals of Neurology, 99(6), 1589-1597. https://doi.org/10.1002/ana.78186
Vancouver
Kamel H, Longstreth WT, Tirschwell DL, Kronmal RA, Elkind MSV, Pauls Q, et al. Apixaban Versus Aspirin and Risk of Hemorrhage in the ARCADIA Trial. Annals of Neurology. 2026;99(6):1589-1597. doi:10.1002/ana.78186
BibTeX
@article{Kamel2026,
author = {Kamel, Hooman and Longstreth, W T and Tirschwell, David L and Kronmal, Richard A and Elkind, Mitchell S V and Pauls, Qi and Garcia, Rebeca Aragon and Plummer, Pamela and Sabagha, Noor and Ammar, Abdalla and Healey, Jeff S and Shoamanesh, Ashkan and Sheth, Kevin N and Broderick, Joseph P and Navi, Babak B and ARCADIA Investigators, ARCADIA Investigators},
title = {Apixaban Versus Aspirin and Risk of Hemorrhage in the ARCADIA Trial},
journal = {Annals of Neurology},
year = {2026},
volume = {99},
number = {6},
pages = {1589--1597},
doi = {10.1002/ana.78186}
}
EUVIMED